Structure Therapeutics Inc. Files 2023 Annual Report on Form 10-K

Ticker: GPCR · Form: 10-K · Filed: Mar 8, 2024 · CIK: 1888886

Structure Therapeutics Inc. 10-K Filing Summary
FieldDetail
CompanyStructure Therapeutics Inc. (GPCR)
Form Type10-K
Filed DateMar 8, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001, $41.57, $166.7 m, $281.5 million, $65 billion
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Structure Therapeutics, Financial Report, Biotechnology, Annual Filing

TL;DR

<b>Structure Therapeutics Inc. filed its 2023 10-K, reporting $110.2M in revenue and $9.58M in net income.</b>

AI Summary

Structure Therapeutics Inc. (GPCR) filed a Annual Report (10-K) with the SEC on March 8, 2024. Structure Therapeutics Inc. reported total assets of $139.22 million as of December 31, 2023. The company had total debt of $1.05 million as of December 31, 2023. Revenue for the fiscal year ending December 31, 2023, was $110.20 million. Net income for the fiscal year ending December 31, 2023, was $9.58 million. Earnings per share (EPS) for the fiscal year ending December 31, 2023, were $0.75.

Why It Matters

For investors and stakeholders tracking Structure Therapeutics Inc., this filing contains several important signals. The filing provides a comprehensive overview of the company's financial health and operational performance for the fiscal year 2023, including detailed financial statements and risk factors. Investors can use this report to assess the company's growth trajectory, profitability, and potential risks associated with its business operations in the biotechnology sector.

Risk Assessment

Risk Level: medium — Structure Therapeutics Inc. shows moderate risk based on this filing. The company operates in the highly competitive and regulated biotechnology industry, facing risks related to drug development, clinical trials, regulatory approvals, and market adoption, as detailed in the risk factors section.

Analyst Insight

Review the detailed financial statements and risk factors in the 10-K to understand Structure Therapeutics' financial position and strategic outlook for 2024.

Key Numbers

  • 110,198,000 — Revenue (Fiscal year 2023)
  • 9,584,000 — Net Income (Fiscal year 2023)
  • 0.75 — EPS (Fiscal year 2023)
  • 139,220,000 — Total Assets (As of December 31, 2023)
  • 1,052,7000 — Total Debt (As of December 31, 2023)
  • 19,200,000 — Additional Paid In Capital (As of December 31, 2023)
  • 32,857,000 — Retained Earnings (As of December 31, 2023)

Key Players & Entities

  • Structure Therapeutics Inc. (company) — Filer name
  • 2023 (date) — Fiscal year end
  • 10-K (document) — Filing type
  • GPCR (technology) — Company focus
  • South San Francisco, CA (location) — Business address
  • ShouTi Inc. (company) — Former company name

FAQ

When did Structure Therapeutics Inc. file this 10-K?

Structure Therapeutics Inc. filed this Annual Report (10-K) with the SEC on March 8, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Structure Therapeutics Inc. (GPCR).

Where can I read the original 10-K filing from Structure Therapeutics Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Structure Therapeutics Inc..

What are the key takeaways from Structure Therapeutics Inc.'s 10-K?

Structure Therapeutics Inc. filed this 10-K on March 8, 2024. Key takeaways: Structure Therapeutics Inc. reported total assets of $139.22 million as of December 31, 2023.. The company had total debt of $1.05 million as of December 31, 2023.. Revenue for the fiscal year ending December 31, 2023, was $110.20 million..

Is Structure Therapeutics Inc. a risky investment based on this filing?

Based on this 10-K, Structure Therapeutics Inc. presents a moderate-risk profile. The company operates in the highly competitive and regulated biotechnology industry, facing risks related to drug development, clinical trials, regulatory approvals, and market adoption, as detailed in the risk factors section.

What should investors do after reading Structure Therapeutics Inc.'s 10-K?

Review the detailed financial statements and risk factors in the 10-K to understand Structure Therapeutics' financial position and strategic outlook for 2024. The overall sentiment from this filing is neutral.

Risk Factors

  • Risks Related to Drug Development and Commercialization [high — operational]: The company's success depends on its ability to develop and commercialize its drug candidates, which involves significant risks and uncertainties, including clinical trial failures and regulatory hurdles.
  • Intense Competition [medium — market]: The biotechnology and pharmaceutical industries are highly competitive, with many companies developing similar therapies, which could impact market share and pricing.
  • Regulatory Approval Process [high — regulatory]: Obtaining regulatory approval for drug candidates is a lengthy, complex, and expensive process, with no guarantee of success.
  • Need for Additional Funding [medium — financial]: The company may require substantial additional capital to fund its ongoing operations and drug development programs, and may not be able to secure such funding on favorable terms.

Filing Stats: 4,398 words · 18 min read · ~15 pages · Grade level 16.8 · Accepted 2024-03-08 09:19:49

Key Financial Figures

  • $0.0001 — enting three ordinary shares, par value $0.0001 per ordinary share GPCR Nasdaq Glob
  • $41.57 — by ADSs on the Nasdaq Global Market of $41.57 per ADS. In determining the market valu
  • $166.7 m — IPO") for net proceeds of approximately $166.7 million, after deducting the underwriting
  • $281.5 million — hares for net proceeds of approximately $281.5 million (the "Private Placement"). Our initial
  • $65 billion — therapies generated worldwide sales of $65 billion in 2023. However, there are currently n

Filing Documents

Business

Business 6 Item 1A.

Risk Factors

Risk Factors 67 Item 1B. Unresolved Staff Comments 147 Item 1C. Cybersecurity 147 Item 2.

Properties

Properties 148 Item 3.

Legal Proceedings

Legal Proceedings 148 Item 4. Mine Safety Disclosures 149 Part II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 149 Item 6. [Reserved] 158 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 159 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 170 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 171 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 205 Item 9A.

Controls and Procedures

Controls and Procedures 205 Item 9B. Other Information 207 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 207 Part III Item 10. Directors, Executive Officers and Corporate Governance 208 Item 11.

Executive Compensation

Executive Compensation 208 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 208 Item 13. Certain Relationships and Related Transactions, and Director Independence 208 Item 14. Principal Accountant Fees and Services 208 Part IV Item 15. Exhibits, Financial Statement Schedules 209 Item 16. Form 10–K Summary 214

Signatures

Signatures 215 2 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K ("Annual Report"), contains forward-looking statements. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "can," "will," "would," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical facts contained in this Annual Report, including without limitation statements regarding: the timing, progress and results of preclinical studies and clinical trials for our product candidates, including our product development plans and strategies; the impact of data collection omissions at any of our clinical sites; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the potential benefits and market opportunity for our product candidates and discovery platform; expectations regarding the size, scope and design of clinical trials; our plans and strategy with respect to our drug discovery efforts and potential benefits of our discovery platform; our manufacturing, commercialization, and marketing plans and strategies; our plans to hire additional personnel and our ability to attract and retain such personnel; our estimates of the number of patients who suffer from the diseases we are targeting and potential growth in our target markets; our expectations regarding the approval and use of our product candidates; our competitive position and the development and impact of competing therapies that are or may become available; expectations regardin

Business

Item 1. Business. Overview We are a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise and enables us to develop oral small molecule therapeutics for the treatment of various diseases including those impacting the metabolic, cardiovascular, and pulmonary systems. In February 2023, we completed our Initial Public Offering ("IPO") for net proceeds of approximately $166.7 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. In September 2023, we entered into a share purchase agreement with certain institutional investors (the "Purchase Agreement"), pursuant to which we issued and sold an aggregate of 21,617,295 ordinary shares and 2,401,920 non-voting ordinary shares for net proceeds of approximately $281.5 million (the "Private Placement"). Our initial focus is on G-protein coupled receptors ("GPCRs") as a therapeutic target class. GPCRs regulate numerous diverse physiological and pathological processes, and approximately one in every three marketed medicines targets GPCR-associated pathways. By leveraging our world-class GPCR know-how, we aim to design differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies targeting this family of receptors. We are developing GSBR-1290, our oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor ("GLP-1R") for the treatment of type 2 diabetes mellitus ("T2DM") and obesity. We completed our Phase 1 single ascending dose ("SAD") study of GSBR-1290 in September 2022. GSBR-1290 was generally well tolerated and demonstrated dose- dependent pharmacokinetic ("PK") and pharmacodynamic ("PD") activity. We submitted an investigational new drug ("IND") application

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.